JPMorgan Chase & Co. Has $1.53 Million Holdings in Evolus, Inc. (NASDAQ:EOLS)

JPMorgan Chase & Co. lowered its holdings in shares of Evolus, Inc. (NASDAQ:EOLS - Free Report) by 18.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 138,149 shares of the company's stock after selling 31,777 shares during the period. JPMorgan Chase & Co. owned approximately 0.22% of Evolus worth $1,525,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the business. Jane Street Group LLC increased its position in shares of Evolus by 47.0% during the 3rd quarter. Jane Street Group LLC now owns 91,899 shares of the company's stock valued at $1,489,000 after purchasing an additional 29,396 shares during the period. Barclays PLC boosted its holdings in shares of Evolus by 268.0% in the third quarter. Barclays PLC now owns 93,662 shares of the company's stock worth $1,518,000 after buying an additional 68,213 shares during the period. Geode Capital Management LLC increased its position in shares of Evolus by 0.9% in the third quarter. Geode Capital Management LLC now owns 1,210,621 shares of the company's stock worth $19,616,000 after acquiring an additional 11,027 shares in the last quarter. Lord Abbett & CO. LLC boosted its stake in Evolus by 23.4% in the 3rd quarter. Lord Abbett & CO. LLC now owns 995,449 shares of the company's stock worth $16,126,000 after purchasing an additional 188,685 shares during the period. Finally, KBC Group NV acquired a new stake in Evolus during the 4th quarter valued at $49,000. Institutional investors and hedge funds own 90.69% of the company's stock.

Analyst Upgrades and Downgrades

EOLS has been the topic of a number of research analyst reports. HC Wainwright reiterated a "buy" rating and set a $27.00 price target on shares of Evolus in a report on Thursday, April 10th. BTIG Research assumed coverage on shares of Evolus in a research report on Thursday, April 17th. They issued a "buy" rating and a $21.00 price target for the company. Needham & Company LLC reaffirmed a "buy" rating and set a $22.00 price objective on shares of Evolus in a research report on Wednesday, April 9th. Finally, Barclays increased their target price on shares of Evolus from $22.00 to $25.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $23.75.

Insider Activity

In other Evolus news, CFO Sandra Beaver sold 8,996 shares of the company's stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total transaction of $119,286.96. Following the completion of the sale, the chief financial officer now owns 173,583 shares of the company's stock, valued at $2,301,710.58. This represents a 4.93 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider David Moatazedi sold 6,251 shares of Evolus stock in a transaction that occurred on Thursday, March 27th. The shares were sold at an average price of $12.40, for a total transaction of $77,512.40. Following the completion of the transaction, the insider now directly owns 508,619 shares in the company, valued at approximately $6,306,875.60. This represents a 1.21 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 60,575 shares of company stock valued at $794,369. Insiders own 6.10% of the company's stock.

Evolus Stock Up 0.9 %

Evolus stock traded up $0.10 during mid-day trading on Thursday, hitting $11.50. 45,374 shares of the company's stock were exchanged, compared to its average volume of 664,885. Evolus, Inc. has a 1-year low of $8.67 and a 1-year high of $17.82. The stock has a 50 day moving average of $12.07 and a two-hundred day moving average of $12.84. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58. The stock has a market cap of $731.25 million, a P/E ratio of -12.60 and a beta of 0.97.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.